KL‑6, ET‑1 and S100A9 levels in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea.

MLA

Bouloukaki, Izolde, et al. “KL‑6, ET‑1 and S100A9 Levels in Patients with Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea.” Experimental & Therapeutic Medicine, vol. 29, no. 1, Jan. 2025, p. N.PAG. EBSCOhost, https://doi.org/10.3892/etm.2024.12766.

APA

Bouloukaki, I., Michelakis, S., Tsitoura, E., Vasarmidi, E., Koutoulaki, C., Tzanakis, N., Schiza, S., & Antoniou, K. M. (2025). KL‑6, ET‑1 and S100A9 levels in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea. Experimental & Therapeutic Medicine, 29(1), N.PAG. https://doi.org/10.3892/etm.2024.12766

Chicago

Bouloukaki, Izolde, Stylianos Michelakis, Eliza Tsitoura, Eirini Vasarmidi, Chara Koutoulaki, Nikolaos Tzanakis, Sophia Schiza, and Katerina M. Antoniou. 2025. “KL‑6, ET‑1 and S100A9 Levels in Patients with Idiopathic Pulmonary Fibrosis and Obstructive Sleep Apnea.” Experimental & Therapeutic Medicine 29 (1): N.PAG. doi:10.3892/etm.2024.12766.